Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome Therapeutics has demonstrated steady quarter-over-quarter revenue growth, surpassing Moderna's quarterly revenue by Q2 2026 despite starting from a much smaller base. Meanwhile, Moderna has experienced significant revenue volatility, with sharp declines following peaks, largely due to reduced COVID-19 vaccine adoption and underperforming RSV vaccine sales. Axsome's three-drug portfolio shows promise with multiple clinical trials underway, while Moderna faces challenges from overreliance on products that have lost market traction.